organization · Reporting owner
Morningside Venture Investments Ltd
Disclosed activity across 6 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Apellis Pharmaceuticals, Inc.APLS · Entity 47322 | 10% owner | November 18, 2021 | November 18, 2021 |
| Apnimed, Inc.APMD · Entity 4910 | 10% owner | August 03, 2026 | August 05, 2026 |
| GreenLight Biosciences Holdings, PBCGRNA · Entity 111075 | 10% owner | July 24, 2023 | July 25, 2023 |
| Kezar Life Sciences, Inc.KZR · Entity 12111 | 10% owner | August 15, 2023 | August 17, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Apellis Pharmaceuticals, Inc.
Report date November 18, 2021 · Filed November 18, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,806,342 |
Reported balance
After 2021-11-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-11-18 · Purchase · Acquired 250,000 · Balance 12,806,342 F1: Frances Anne Elizabeth Richard, Cheung Ka Ho, Jill Marie Franklin and Peter Stuart Allenby Edwards, the directors of Morningside Venture Investments, Ltd. ("MVIL"), share voting and dispositive control over the shares held by MVIL. |
Filing footnotes · ownership attribution and instrument terms
F1: Frances Anne Elizabeth Richard, Cheung Ka Ho, Jill Marie Franklin and Peter Stuart Allenby Edwards, the directors of Morningside Venture Investments, Ltd. ("MVIL"), share voting and dispositive control over the shares held by MVIL.
Apnimed, Inc.
Report date August 03, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Last balance in matching sequence
After 2026-08-03 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-08-03 · Conversion · Acquired 6,840,213 · Balance 6,840,213 F1: Each share of convertible preferred stock ("Convertible Preferred Stock") was convertible into one share of Class A common stock ("Class A Common Stock") at any time at the option of the holder into such number of fully paid and non-assessable shares of Class A Common Stock as was determined by dividing the original issuance price of each series of Convertible Preferred Stock by each series' conversion price in effect at the time of conversion. The Convertible Preferred Stock reported herein automatically converted immediately prior to the closing of the Issuer's initial public offering (the "IPO") into 6,840,213 shares of Class A Common Stock without payment of additional consideration. The Convertible Preferred Stock had no expiration date. F2: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards, and Cheung Ka Ho are the directors of Morningside Venture Investments Limited ("Morningside") and share voting and dispositive power with respect to the securities held by Morningside and MVIL, LLC, Morningside's wholly-owned subsidiary. Ms. Richard, Ms. Franklin, Mr. Edwards, and Mr. Cheung each disclaim ownership of the securities owned by Morningside and MVIL, LLC. Row 2 · 2026-08-03 · Other · Disposed 6,840,213 · Balance 0 F3: Following the conversion of all outstanding shares of the Issuer's Convertible Preferred Stock, Class B common stock, Class C common stock, and Convertible Promissory Notes (the "Notes") into shares of Class A Common Stock immediately prior to the closing of the IPO, each share of Class A Common Stock was then reclassified into one share of common stock ("Common Stock") in a transaction exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") pursuant to Rule 16b-7 thereunder (the "Reclassification"). F2: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards, and Cheung Ka Ho are the directors of Morningside Venture Investments Limited ("Morningside") and share voting and dispositive power with respect to the securities held by Morningside and MVIL, LLC, Morningside's wholly-owned subsidiary. Ms. Richard, Ms. Franklin, Mr. Edwards, and Mr. Cheung each disclaim ownership of the securities owned by Morningside and MVIL, LLC. |
| Common StockSEC Table I · non-derivative | Direct | 7,152,713 |
Last balance in matching sequence
After 2026-08-03 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 3 · 2026-08-03 · Other · Acquired 6,840,213 · Balance 6,840,213 F3: Following the conversion of all outstanding shares of the Issuer's Convertible Preferred Stock, Class B common stock, Class C common stock, and Convertible Promissory Notes (the "Notes") into shares of Class A Common Stock immediately prior to the closing of the IPO, each share of Class A Common Stock was then reclassified into one share of common stock ("Common Stock") in a transaction exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") pursuant to Rule 16b-7 thereunder (the "Reclassification"). F2: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards, and Cheung Ka Ho are the directors of Morningside Venture Investments Limited ("Morningside") and share voting and dispositive power with respect to the securities held by Morningside and MVIL, LLC, Morningside's wholly-owned subsidiary. Ms. Richard, Ms. Franklin, Mr. Edwards, and Mr. Cheung each disclaim ownership of the securities owned by Morningside and MVIL, LLC. Row 4 · 2026-08-03 · Purchase · Acquired 312,500 · Balance 7,152,713 F2: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards, and Cheung Ka Ho are the directors of Morningside Venture Investments Limited ("Morningside") and share voting and dispositive power with respect to the securities held by Morningside and MVIL, LLC, Morningside's wholly-owned subsidiary. Ms. Richard, Ms. Franklin, Mr. Edwards, and Mr. Cheung each disclaim ownership of the securities owned by Morningside and MVIL, LLC. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy MVIL, LLC | 0 |
Last balance in matching sequence
After 2026-08-03 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 5 · 2026-08-03 · Conversion · Acquired 75,624 · Balance 75,624 F4: The Notes were originally issued on September 17, 2025, with the Reporting Person acquiring a Note with a principal amount of $1,000,000. The Notes earned interest at a rate of 8% annually until March 31, 2026, and thereafter earned interest at a rate of 15% annually until repaid or converted. The Notes included a conversion feature providing for automatic conversion into Class A Common Stock at or immediately prior to the closing of the IPO at a 10% discount to the IPO price per share. As a result of the IPO pricing on July 30, 2026, at a price of $16 per share, this Note automatically converted into shares of Class A Common Stock immediately prior to the closing of the IPO on August 3, 2026, at a conversion price of $14.40. F2: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards, and Cheung Ka Ho are the directors of Morningside Venture Investments Limited ("Morningside") and share voting and dispositive power with respect to the securities held by Morningside and MVIL, LLC, Morningside's wholly-owned subsidiary. Ms. Richard, Ms. Franklin, Mr. Edwards, and Mr. Cheung each disclaim ownership of the securities owned by Morningside and MVIL, LLC. F6: Represents securities held by MVIL, LLC. Row 6 · 2026-08-03 · Other · Disposed 75,624 · Balance 0 F3: Following the conversion of all outstanding shares of the Issuer's Convertible Preferred Stock, Class B common stock, Class C common stock, and Convertible Promissory Notes (the "Notes") into shares of Class A Common Stock immediately prior to the closing of the IPO, each share of Class A Common Stock was then reclassified into one share of common stock ("Common Stock") in a transaction exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") pursuant to Rule 16b-7 thereunder (the "Reclassification"). F2: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards, and Cheung Ka Ho are the directors of Morningside Venture Investments Limited ("Morningside") and share voting and dispositive power with respect to the securities held by Morningside and MVIL, LLC, Morningside's wholly-owned subsidiary. Ms. Richard, Ms. Franklin, Mr. Edwards, and Mr. Cheung each disclaim ownership of the securities owned by Morningside and MVIL, LLC. F6: Represents securities held by MVIL, LLC. |
| Common StockSEC Table I · non-derivative | IndirectBy MVIL, LLC | 75,624 |
Reported balance
After 2026-08-03 transaction · row 7
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 7 · 2026-08-03 · Other · Acquired 75,624 · Balance 75,624 F3: Following the conversion of all outstanding shares of the Issuer's Convertible Preferred Stock, Class B common stock, Class C common stock, and Convertible Promissory Notes (the "Notes") into shares of Class A Common Stock immediately prior to the closing of the IPO, each share of Class A Common Stock was then reclassified into one share of common stock ("Common Stock") in a transaction exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") pursuant to Rule 16b-7 thereunder (the "Reclassification"). F2: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards, and Cheung Ka Ho are the directors of Morningside Venture Investments Limited ("Morningside") and share voting and dispositive power with respect to the securities held by Morningside and MVIL, LLC, Morningside's wholly-owned subsidiary. Ms. Richard, Ms. Franklin, Mr. Edwards, and Mr. Cheung each disclaim ownership of the securities owned by Morningside and MVIL, LLC. F6: Represents securities held by MVIL, LLC. |
| Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-08-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-08-03 · Conversion · Disposed 9,227,454 · Balance 0 F1: Each share of convertible preferred stock ("Convertible Preferred Stock") was convertible into one share of Class A common stock ("Class A Common Stock") at any time at the option of the holder into such number of fully paid and non-assessable shares of Class A Common Stock as was determined by dividing the original issuance price of each series of Convertible Preferred Stock by each series' conversion price in effect at the time of conversion. The Convertible Preferred Stock reported herein automatically converted immediately prior to the closing of the Issuer's initial public offering (the "IPO") into 6,840,213 shares of Class A Common Stock without payment of additional consideration. The Convertible Preferred Stock had no expiration date. F2: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards, and Cheung Ka Ho are the directors of Morningside Venture Investments Limited ("Morningside") and share voting and dispositive power with respect to the securities held by Morningside and MVIL, LLC, Morningside's wholly-owned subsidiary. Ms. Richard, Ms. Franklin, Mr. Edwards, and Mr. Cheung each disclaim ownership of the securities owned by Morningside and MVIL, LLC. |
| Convertible Promissory NoteSEC Table II · derivative / convertible security · Conversion / exercise price $14.40 | IndirectBy MVIL, LLC | 0 |
Reported balance
After 2026-08-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-03 · Conversion · Disposed 1,088,986.3 · Balance 0 F4: The Notes were originally issued on September 17, 2025, with the Reporting Person acquiring a Note with a principal amount of $1,000,000. The Notes earned interest at a rate of 8% annually until March 31, 2026, and thereafter earned interest at a rate of 15% annually until repaid or converted. The Notes included a conversion feature providing for automatic conversion into Class A Common Stock at or immediately prior to the closing of the IPO at a 10% discount to the IPO price per share. As a result of the IPO pricing on July 30, 2026, at a price of $16 per share, this Note automatically converted into shares of Class A Common Stock immediately prior to the closing of the IPO on August 3, 2026, at a conversion price of $14.40. F5: The Notes were scheduled to mature on September 17, 2027, but converted automatically upon the closing of the IPO on August 3, 2026, prior to the maturity date. F2: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards, and Cheung Ka Ho are the directors of Morningside Venture Investments Limited ("Morningside") and share voting and dispositive power with respect to the securities held by Morningside and MVIL, LLC, Morningside's wholly-owned subsidiary. Ms. Richard, Ms. Franklin, Mr. Edwards, and Mr. Cheung each disclaim ownership of the securities owned by Morningside and MVIL, LLC. F6: Represents securities held by MVIL, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of convertible preferred stock ("Convertible Preferred Stock") was convertible into one share of Class A common stock ("Class A Common Stock") at any time at the option of the holder into such number of fully paid and non-assessable shares of Class A Common Stock as was determined by dividing the original issuance price of each series of Convertible Preferred Stock by each series' conversion price in effect at the time of conversion. The Convertible Preferred Stock reported herein automatically converted immediately prior to the closing of the Issuer's initial public offering (the "IPO") into 6,840,213 shares of Class A Common Stock without payment of additional consideration. The Convertible Preferred Stock had no expiration date.
F2: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards, and Cheung Ka Ho are the directors of Morningside Venture Investments Limited ("Morningside") and share voting and dispositive power with respect to the securities held by Morningside and MVIL, LLC, Morningside's wholly-owned subsidiary. Ms. Richard, Ms. Franklin, Mr. Edwards, and Mr. Cheung each disclaim ownership of the securities owned by Morningside and MVIL, LLC.
F3: Following the conversion of all outstanding shares of the Issuer's Convertible Preferred Stock, Class B common stock, Class C common stock, and Convertible Promissory Notes (the "Notes") into shares of Class A Common Stock immediately prior to the closing of the IPO, each share of Class A Common Stock was then reclassified into one share of common stock ("Common Stock") in a transaction exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") pursuant to Rule 16b-7 thereunder (the "Reclassification").
F4: The Notes were originally issued on September 17, 2025, with the Reporting Person acquiring a Note with a principal amount of $1,000,000. The Notes earned interest at a rate of 8% annually until March 31, 2026, and thereafter earned interest at a rate of 15% annually until repaid or converted. The Notes included a conversion feature providing for automatic conversion into Class A Common Stock at or immediately prior to the closing of the IPO at a 10% discount to the IPO price per share. As a result of the IPO pricing on July 30, 2026, at a price of $16 per share, this Note automatically converted into shares of Class A Common Stock immediately prior to the closing of the IPO on August 3, 2026, at a conversion price of $14.40.
F5: The Notes were scheduled to mature on September 17, 2027, but converted automatically upon the closing of the IPO on August 3, 2026, prior to the maturity date.
F6: Represents securities held by MVIL, LLC.
GreenLight Biosciences Holdings, PBC
Report date July 24, 2023 · Filed July 25, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-07-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-07-24 · Other · Disposed 16,919,155 · Balance 0 F1: Consists of 15,919,155 shares of common stock held directly by Morningside Venture Investments Limited and 1,000,000 shares of common stock held by MVIL, LLC, its wholly owned subsidiary. F2: In connection with the merger of the Issuer with a wholly owned subsidiary of SW ParentCo, Inc. ("Parent"), the Reporting Persons entered into a Contribution and Exchange Agreement pursuant to which, on July 21, 2023, they contributed all of their shares of the Issuer's common stock to Parent in exchange for shares of preferred stock of Parent. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of 15,919,155 shares of common stock held directly by Morningside Venture Investments Limited and 1,000,000 shares of common stock held by MVIL, LLC, its wholly owned subsidiary.
F2: In connection with the merger of the Issuer with a wholly owned subsidiary of SW ParentCo, Inc. ("Parent"), the Reporting Persons entered into a Contribution and Exchange Agreement pursuant to which, on July 21, 2023, they contributed all of their shares of the Issuer's common stock to Parent in exchange for shares of preferred stock of Parent.
Kezar Life Sciences, Inc.
Report date August 15, 2023 · Filed August 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,947,993 |
Reported balance
After 2023-08-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-08-15 · Gift · Disposed 3,500,000 · Balance 1,947,993 F1: Reflects the gift / charitable donation of common stock to a 501(c)(3) non-profit organization. This is not a market transaction, thus no price has been reported. No value was received by the seller for the gifted shares. F2: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, the directors of Morningside Venture Investments Limited ("MVIL"), share voting and dispositive control over the shares held by MVIL and disclaim any personal beneficial ownership of any shares held by MVIL. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the gift / charitable donation of common stock to a 501(c)(3) non-profit organization. This is not a market transaction, thus no price has been reported. No value was received by the seller for the gifted shares.
F2: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, the directors of Morningside Venture Investments Limited ("MVIL"), share voting and dispositive control over the shares held by MVIL and disclaim any personal beneficial ownership of any shares held by MVIL.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Amylyx Pharmaceuticals, Inc.
Report date August 15, 2023 · Filed August 17, 2023
Section 16 reporting ended · disclosed 2023-08-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,997,302 |
Reported balance
After 2023-08-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-08-15 · Gift · Disposed 2,000,000 · Balance 4,997,302 F1: Reflects the gift / charitable donation of common stock to a 501(c)(3) non-profit organization. This is not a market transaction, thus no price has been reported. No value was received by the seller for the gifted shares. F2: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, the directors of Morningside Venture Investments Limited ("MVIL"), share voting and dispositive control over the shares held by MVIL and disclaim any personal beneficial ownership of any shares held by MVIL. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the gift / charitable donation of common stock to a 501(c)(3) non-profit organization. This is not a market transaction, thus no price has been reported. No value was received by the seller for the gifted shares.
F2: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, the directors of Morningside Venture Investments Limited ("MVIL"), share voting and dispositive control over the shares held by MVIL and disclaim any personal beneficial ownership of any shares held by MVIL.
Liquidia Technologies Inc
Report date July 30, 2018 · Filed August 01, 2018
Section 16 reporting ended · disclosed 2018-08-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 552,728 |
Last balance in matching sequence
After 2018-07-30 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2018-07-30 · Conversion · Acquired 442,819 · Balance 442,819 F1: The Series C preferred stock had no expiration date and automatically converted into the Issuer's common stock on approximately a 0.1295-for-1 basis immediately prior to the closing of the Issuer's initial public offering. F4: Louise Mary Garbarino, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments, Ltd. ("MVIL"), share voting and dispositive control over the shares held by MVIL. Row 2 · 2018-07-30 · Conversion · Acquired 109,909 · Balance 552,728 F2: The Series D preferred stock had no expiration date and automatically converted into the Issuer's common stock on approximately a 0.0594-for-1 basis immediately prior to the closing of the Issuer's initial public offering. F4: Louise Mary Garbarino, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments, Ltd. ("MVIL"), share voting and dispositive control over the shares held by MVIL. |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-07-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-07-30 · Conversion · Disposed 3,420,516 · Balance 0 F1: The Series C preferred stock had no expiration date and automatically converted into the Issuer's common stock on approximately a 0.1295-for-1 basis immediately prior to the closing of the Issuer's initial public offering. F4: Louise Mary Garbarino, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments, Ltd. ("MVIL"), share voting and dispositive control over the shares held by MVIL. |
| Series D Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-07-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-07-30 · Conversion · Disposed 1,849,490 · Balance 0 F2: The Series D preferred stock had no expiration date and automatically converted into the Issuer's common stock on approximately a 0.0594-for-1 basis immediately prior to the closing of the Issuer's initial public offering. F4: Louise Mary Garbarino, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments, Ltd. ("MVIL"), share voting and dispositive control over the shares held by MVIL. |
| Warrant to purchase Series D Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2026-12-31 | Direct | 0 |
Reported balance
After 2018-07-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-07-30 · Other · Disposed 319,664 · Balance 0 F3: Immediately prior to the closing of the Issuer's initial public offering and without payment of further consideration, the Warrants to purchase Series D Preferred Stock automatically became exercisable to purchase the Issuer's common stock. The transaction is listed solely for the purpose of reporting the change of the title and amount of securities underlying the warrant. F4: Louise Mary Garbarino, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments, Ltd. ("MVIL"), share voting and dispositive control over the shares held by MVIL. |
| Warrant to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2026-12-31 | Direct | 18,996 |
Reported balance
After 2018-07-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-07-30 · Other · Acquired 18,996 · Balance 18,996 F3: Immediately prior to the closing of the Issuer's initial public offering and without payment of further consideration, the Warrants to purchase Series D Preferred Stock automatically became exercisable to purchase the Issuer's common stock. The transaction is listed solely for the purpose of reporting the change of the title and amount of securities underlying the warrant. F4: Louise Mary Garbarino, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments, Ltd. ("MVIL"), share voting and dispositive control over the shares held by MVIL. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series C preferred stock had no expiration date and automatically converted into the Issuer's common stock on approximately a 0.1295-for-1 basis immediately prior to the closing of the Issuer's initial public offering.
F2: The Series D preferred stock had no expiration date and automatically converted into the Issuer's common stock on approximately a 0.0594-for-1 basis immediately prior to the closing of the Issuer's initial public offering.
F3: Immediately prior to the closing of the Issuer's initial public offering and without payment of further consideration, the Warrants to purchase Series D Preferred Stock automatically became exercisable to purchase the Issuer's common stock. The transaction is listed solely for the purpose of reporting the change of the title and amount of securities underlying the warrant.
F4: Louise Mary Garbarino, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments, Ltd. ("MVIL"), share voting and dispositive control over the shares held by MVIL.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 20, 2022 Filed Jan 11, 2023 21:07 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GiftCommon Stock | 33,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-001580 · doc5.xml · nonDerivative · entry 3 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,513,931 Read SEC document |
| September 12, 2022 Filed Jan 11, 2023 21:07 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GiftCommon Stock | 340,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-001580 · doc5.xml · nonDerivative · entry 2 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,547,264 Read SEC document |
| September 12, 2022 Filed Jan 11, 2023 21:07 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GiftCommon Stock | 170,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-001580 · doc5.xml · nonDerivative · entry 1 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,887,264 Read SEC document |
| August 11, 2022 Filed Aug 15, 2022 22:48 UTC | GreenLight Biosciences Holdings, PBC GRNA · Entity 111075 | PurchaseCommon Stock | 3,061,224 | $3.92 | $11,999,998.08 |
DisclosureSEC source: 0000899243-22-028680 · doc4.xml · nonDerivative · entry 1 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,919,155 F1 · kind: Acquired by Morningside Venture Investments Limited ("Morningside") from the Issuer pursuant to a Subscription Agreement dated August 11, 2022. F2 · ownership.direct: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, are the directors of Morningside Venture Investments Limited ("Morningside") and share voting and dispositive power with respect to the securities held by Morningside. Ms. Richard, Ms. Franklin, Mr. Edwards and Mr. Cheung each disclaim beneficial ownership of the securities owned by Morningside and MVIL LLC (as defined below). Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 22:15 UTC | GreenLight Biosciences Holdings, PBC ENVI · Entity 111075 | ConversionClass A Common Stock · Derivative | 1,000,000 | $10.00 | $10,000,000.00 |
DisclosureSEC source: 0000899243-22-004855 · doc4.xml · derivative · entry 4 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the closing of the Issuer's business combination transaction, all Class A Common Stock converted into the same number of shares of the Issuer's Common Stock without payment or further consideration. The Class A Common Stock had no expiration date. F1 · derivative.exercise_date: In connection with the closing of the Issuer's business combination transaction, all Class A Common Stock converted into the same number of shares of the Issuer's Common Stock without payment or further consideration. The Class A Common Stock had no expiration date. F1 · derivative.expiration_date: In connection with the closing of the Issuer's business combination transaction, all Class A Common Stock converted into the same number of shares of the Issuer's Common Stock without payment or further consideration. The Class A Common Stock had no expiration date. F2 · ownership.direct: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, are the directors of Morningside Venture Investments Limited ("Morningside") and share voting and dispositive power with respect to the securities held by Morningside and MVIL, LLC ("MVIL LLC"), Morningside's wholly-owned subsidiary. Cheng Yee Wing and Wong See Wai are the managers of MVIL LLC and share voting and dispositive power with respect to the securities held by MVIL LLC. Ms. Richard, Ms. Franklin, Mr. Edwards and Mr. Cheung each disclaim beneficial ownership of the securities owned by Morningside. Ms. Cheng and Mr. Wong each disclaim ownership of the securities owned by MVIL LLC. F3 · ownership.direct: Represent shares held by MVIL LLC. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 22:15 UTC | GreenLight Biosciences Holdings, PBC ENVI · Entity 111075 | ConversionClass A Common Stock · Derivative | 12,858,188 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-004855 · doc4.xml · derivative · entry 3 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,858,188 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the closing of the Issuer's business combination transaction, all Class A Common Stock converted into the same number of shares of the Issuer's Common Stock without payment or further consideration. The Class A Common Stock had no expiration date. F4 · price: Represent shares of Class A Common Stock received in exchange for shares of GreenLight BioSciences, Inc. in connection with the business combination transaction of the Issuer. F1 · derivative.exercise_date: In connection with the closing of the Issuer's business combination transaction, all Class A Common Stock converted into the same number of shares of the Issuer's Common Stock without payment or further consideration. The Class A Common Stock had no expiration date. F1 · derivative.expiration_date: In connection with the closing of the Issuer's business combination transaction, all Class A Common Stock converted into the same number of shares of the Issuer's Common Stock without payment or further consideration. The Class A Common Stock had no expiration date. F2 · ownership.direct: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, are the directors of Morningside Venture Investments Limited ("Morningside") and share voting and dispositive power with respect to the securities held by Morningside and MVIL, LLC ("MVIL LLC"), Morningside's wholly-owned subsidiary. Cheng Yee Wing and Wong See Wai are the managers of MVIL LLC and share voting and dispositive power with respect to the securities held by MVIL LLC. Ms. Richard, Ms. Franklin, Mr. Edwards and Mr. Cheung each disclaim beneficial ownership of the securities owned by Morningside. Ms. Cheng and Mr. Wong each disclaim ownership of the securities owned by MVIL LLC. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 22:15 UTC | GreenLight Biosciences Holdings, PBC ENVI · Entity 111075 | PurchaseCommon Stock | 1,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-004855 · doc4.xml · nonDerivative · entry 2 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,858,188 F1 · price: In connection with the closing of the Issuer's business combination transaction, all Class A Common Stock converted into the same number of shares of the Issuer's Common Stock without payment or further consideration. The Class A Common Stock had no expiration date. F2 · ownership.direct: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, are the directors of Morningside Venture Investments Limited ("Morningside") and share voting and dispositive power with respect to the securities held by Morningside and MVIL, LLC ("MVIL LLC"), Morningside's wholly-owned subsidiary. Cheng Yee Wing and Wong See Wai are the managers of MVIL LLC and share voting and dispositive power with respect to the securities held by MVIL LLC. Ms. Richard, Ms. Franklin, Mr. Edwards and Mr. Cheung each disclaim beneficial ownership of the securities owned by Morningside. Ms. Cheng and Mr. Wong each disclaim ownership of the securities owned by MVIL LLC. F3 · ownership.direct: Represent shares held by MVIL LLC. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 22:15 UTC | GreenLight Biosciences Holdings, PBC ENVI · Entity 111075 | ConversionCommon Stock | 12,858,188 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-004855 · doc4.xml · nonDerivative · entry 1 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,858,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: In connection with the closing of the Issuer's business combination transaction, all Class A Common Stock converted into the same number of shares of the Issuer's Common Stock without payment or further consideration. The Class A Common Stock had no expiration date. F2 · ownership.direct: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, are the directors of Morningside Venture Investments Limited ("Morningside") and share voting and dispositive power with respect to the securities held by Morningside and MVIL, LLC ("MVIL LLC"), Morningside's wholly-owned subsidiary. Cheng Yee Wing and Wong See Wai are the managers of MVIL LLC and share voting and dispositive power with respect to the securities held by MVIL LLC. Ms. Richard, Ms. Franklin, Mr. Edwards and Mr. Cheung each disclaim beneficial ownership of the securities owned by Morningside. Ms. Cheng and Mr. Wong each disclaim ownership of the securities owned by MVIL LLC. Read SEC document |
| February 02, 2022 Filed Mar 17, 2022 21:11 UTC Amendment | GreenLight Biosciences Holdings, PBC GRNA · Entity 111075 | ConversionClass A Common Stock · Derivative | 1,000,000 | $10.00 | $10,000,000.00 |
DisclosureSEC source: 0000899243-22-011429 · doc4a.xml · derivative · entry 4 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner MVIL, LLC · CIK 0001914583 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the closing of the Issuer's business combination transaction, all Class A Common Stock converted into the same number of shares of the Issuer's Common Stock without payment or further consideration. The Class A Common Stock had no expiration date. F1 · derivative.exercise_date: In connection with the closing of the Issuer's business combination transaction, all Class A Common Stock converted into the same number of shares of the Issuer's Common Stock without payment or further consideration. The Class A Common Stock had no expiration date. F1 · derivative.expiration_date: In connection with the closing of the Issuer's business combination transaction, all Class A Common Stock converted into the same number of shares of the Issuer's Common Stock without payment or further consideration. The Class A Common Stock had no expiration date. F2 · ownership.direct: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho are the directors of Morningside Venture Investments Limited ("Morningside") and share voting and dispositive power with respect to the securities held by Morningside and MVIL, LLC ("MVIL LLC"), Morningside's wholly-owned subsidiary. Cheng Yee Wing Betty and Wong See Wai are the managers of MVIL LLC and share voting and dispositive power with respect to the securities held by MVIL LLC. Ms. Richard, Ms. Franklin, Mr. Edwards and Mr. Cheung each disclaim beneficial ownership of the securities owned by Morningside and MVIL LLC. Ms. Cheng and Mr. Wong each disclaim ownership of the securities owned by MVIL LLC. F3 · ownership.direct: Represent shares held by MVIL LLC. Read SEC document |
| February 02, 2022 Filed Mar 17, 2022 21:11 UTC Amendment | GreenLight Biosciences Holdings, PBC GRNA · Entity 111075 | ConversionClass A Common Stock · Derivative | 12,857,931 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-011429 · doc4a.xml · derivative · entry 3 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner MVIL, LLC · CIK 0001914583 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,857,931 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the closing of the Issuer's business combination transaction, all Class A Common Stock converted into the same number of shares of the Issuer's Common Stock without payment or further consideration. The Class A Common Stock had no expiration date. F4 · price: Represent shares of Class A Common Stock received in exchange for shares of GreenLight BioSciences, Inc. ("Greenlight") in connection with the business combination transaction of the Issuer. This amendment corrects the number of shares of Class A Common Stock received by Morningside upon conversion of Greenlight shares into Class A Common Stock of the Issuer. The previous number of 12,858,188 has been revised to 12,857,936. F1 · derivative.exercise_date: In connection with the closing of the Issuer's business combination transaction, all Class A Common Stock converted into the same number of shares of the Issuer's Common Stock without payment or further consideration. The Class A Common Stock had no expiration date. F1 · derivative.expiration_date: In connection with the closing of the Issuer's business combination transaction, all Class A Common Stock converted into the same number of shares of the Issuer's Common Stock without payment or further consideration. The Class A Common Stock had no expiration date. F2 · ownership.direct: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho are the directors of Morningside Venture Investments Limited ("Morningside") and share voting and dispositive power with respect to the securities held by Morningside and MVIL, LLC ("MVIL LLC"), Morningside's wholly-owned subsidiary. Cheng Yee Wing Betty and Wong See Wai are the managers of MVIL LLC and share voting and dispositive power with respect to the securities held by MVIL LLC. Ms. Richard, Ms. Franklin, Mr. Edwards and Mr. Cheung each disclaim beneficial ownership of the securities owned by Morningside and MVIL LLC. Ms. Cheng and Mr. Wong each disclaim ownership of the securities owned by MVIL LLC. Read SEC document |
| February 02, 2022 Filed Mar 17, 2022 21:11 UTC Amendment | GreenLight Biosciences Holdings, PBC GRNA · Entity 111075 | PurchaseCommon Stock | 1,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-011429 · doc4a.xml · nonDerivative · entry 2 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner MVIL, LLC · CIK 0001914583 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,857,931 F1 · price: In connection with the closing of the Issuer's business combination transaction, all Class A Common Stock converted into the same number of shares of the Issuer's Common Stock without payment or further consideration. The Class A Common Stock had no expiration date. F2 · ownership.direct: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho are the directors of Morningside Venture Investments Limited ("Morningside") and share voting and dispositive power with respect to the securities held by Morningside and MVIL, LLC ("MVIL LLC"), Morningside's wholly-owned subsidiary. Cheng Yee Wing Betty and Wong See Wai are the managers of MVIL LLC and share voting and dispositive power with respect to the securities held by MVIL LLC. Ms. Richard, Ms. Franklin, Mr. Edwards and Mr. Cheung each disclaim beneficial ownership of the securities owned by Morningside and MVIL LLC. Ms. Cheng and Mr. Wong each disclaim ownership of the securities owned by MVIL LLC. F3 · ownership.direct: Represent shares held by MVIL LLC. Read SEC document |
| February 02, 2022 Filed Mar 17, 2022 21:11 UTC Amendment | GreenLight Biosciences Holdings, PBC GRNA · Entity 111075 | ConversionCommon Stock | 12,857,931 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-011429 · doc4a.xml · nonDerivative · entry 1 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner MVIL, LLC · CIK 0001914583 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,857,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: In connection with the closing of the Issuer's business combination transaction, all Class A Common Stock converted into the same number of shares of the Issuer's Common Stock without payment or further consideration. The Class A Common Stock had no expiration date. F2 · ownership.direct: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho are the directors of Morningside Venture Investments Limited ("Morningside") and share voting and dispositive power with respect to the securities held by Morningside and MVIL, LLC ("MVIL LLC"), Morningside's wholly-owned subsidiary. Cheng Yee Wing Betty and Wong See Wai are the managers of MVIL LLC and share voting and dispositive power with respect to the securities held by MVIL LLC. Ms. Richard, Ms. Franklin, Mr. Edwards and Mr. Cheung each disclaim beneficial ownership of the securities owned by Morningside and MVIL LLC. Ms. Cheng and Mr. Wong each disclaim ownership of the securities owned by MVIL LLC. Read SEC document |
| January 11, 2022 Filed Jan 25, 2022 21:46 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | ConversionSeries C-2 Preferred Stock · Derivative | 1,621,544 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-003157 · doc4.xml · derivative · entry 6 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,621,544 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F2 · ownership.direct: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, are the directors of Morningside and share voting and dispositive power with respect to the securities held by Morningside Venture Investments Limited ("Morningside") and MVIL, LLC ("MVIL LLC"), Morningside's wholly-owned subsidiary. Cheng Yee Wing and Wong See Wai are the managers of MVIL LLC and share voting and dispositive power with respect to the securities held by MVIL LLC. Ms. Cheng and Mr. Wong each disclaim ownership of the securities owned by MVIL LLC. F3 · ownership.direct: The shares of Series C-2 Preferred Stock and the Common Stock received upon conversion of the C-2 Preferred Stock are held by MVIL LLC. Read SEC document |
| January 11, 2022 Filed Jan 25, 2022 21:46 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | ConversionSeries C-1 Preferred Stock · Derivative | 974,107 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-003157 · doc4.xml · derivative · entry 5 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 974,107 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F2 · ownership.direct: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, are the directors of Morningside and share voting and dispositive power with respect to the securities held by Morningside Venture Investments Limited ("Morningside") and MVIL, LLC ("MVIL LLC"), Morningside's wholly-owned subsidiary. Cheng Yee Wing and Wong See Wai are the managers of MVIL LLC and share voting and dispositive power with respect to the securities held by MVIL LLC. Ms. Cheng and Mr. Wong each disclaim ownership of the securities owned by MVIL LLC. Read SEC document |
| January 11, 2022 Filed Jan 25, 2022 21:46 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | ConversionSeries B Preferred Stock · Derivative | 6,410,964 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-003157 · doc4.xml · derivative · entry 4 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,410,964 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F2 · ownership.direct: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, are the directors of Morningside and share voting and dispositive power with respect to the securities held by Morningside Venture Investments Limited ("Morningside") and MVIL, LLC ("MVIL LLC"), Morningside's wholly-owned subsidiary. Cheng Yee Wing and Wong See Wai are the managers of MVIL LLC and share voting and dispositive power with respect to the securities held by MVIL LLC. Ms. Cheng and Mr. Wong each disclaim ownership of the securities owned by MVIL LLC. Read SEC document |
| January 11, 2022 Filed Jan 25, 2022 21:46 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | ConversionSeries A Preferred Stock · Derivative | 1,409,035 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-003157 · doc4.xml · derivative · entry 3 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,409,035 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F2 · ownership.direct: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, are the directors of Morningside and share voting and dispositive power with respect to the securities held by Morningside Venture Investments Limited ("Morningside") and MVIL, LLC ("MVIL LLC"), Morningside's wholly-owned subsidiary. Cheng Yee Wing and Wong See Wai are the managers of MVIL LLC and share voting and dispositive power with respect to the securities held by MVIL LLC. Ms. Cheng and Mr. Wong each disclaim ownership of the securities owned by MVIL LLC. Read SEC document |
| January 11, 2022 Filed Jan 25, 2022 21:46 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | PurchaseCommon Stock | 263,158 | $19.00 | $5,000,002.00 |
DisclosureSEC source: 0000899243-22-003157 · doc4.xml · nonDerivative · entry 2 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,678,808 F2 · ownership.direct: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, are the directors of Morningside and share voting and dispositive power with respect to the securities held by Morningside Venture Investments Limited ("Morningside") and MVIL, LLC ("MVIL LLC"), Morningside's wholly-owned subsidiary. Cheng Yee Wing and Wong See Wai are the managers of MVIL LLC and share voting and dispositive power with respect to the securities held by MVIL LLC. Ms. Cheng and Mr. Wong each disclaim ownership of the securities owned by MVIL LLC. Read SEC document |
| January 11, 2022 Filed Jan 25, 2022 21:46 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | ConversionCommon Stock | 10,415,650 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-003157 · doc4.xml · nonDerivative · entry 1 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,415,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F2 · ownership.direct: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, are the directors of Morningside and share voting and dispositive power with respect to the securities held by Morningside Venture Investments Limited ("Morningside") and MVIL, LLC ("MVIL LLC"), Morningside's wholly-owned subsidiary. Cheng Yee Wing and Wong See Wai are the managers of MVIL LLC and share voting and dispositive power with respect to the securities held by MVIL LLC. Ms. Cheng and Mr. Wong each disclaim ownership of the securities owned by MVIL LLC. F3 · ownership.direct: The shares of Series C-2 Preferred Stock and the Common Stock received upon conversion of the C-2 Preferred Stock are held by MVIL LLC. Read SEC document |
| January 11, 2022 Filed Mar 17, 2022 21:14 UTC Amendment | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | ConversionSeries C-2 Preferred Stock · Derivative | 1,621,544 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-011432 · doc4a.xml · derivative · entry 6 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner MVIL, LLC · CIK 0001914583 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,621,544 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, are the directors of Morningside Venture Investments Limited ("Morningside") and share voting and dispositive power with respect to the securities held by Morningside and MVIL, LLC ("MVIL LLC"), Morningside's wholly-owned subsidiary. Cheng Yee Wing Betty and Wong See Wai are the managers of MVIL LLC and share voting and dispositive power with respect to the securities held by MVIL LLC. Ms. Cheng and Mr. Wong each disclaim ownership of the securities owned by MVIL LLC. F3 · ownership.nature: The shares of Series C-2 Preferred Stock and the Common Stock received upon conversion of the C-2 Preferred Stock are held by MVIL LLC. Read SEC document |
| January 11, 2022 Filed Mar 17, 2022 21:14 UTC Amendment | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | ConversionSeries C-1 Preferred Stock · Derivative | 974,107 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-011432 · doc4a.xml · derivative · entry 5 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner MVIL, LLC · CIK 0001914583 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 974,107 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, are the directors of Morningside Venture Investments Limited ("Morningside") and share voting and dispositive power with respect to the securities held by Morningside and MVIL, LLC ("MVIL LLC"), Morningside's wholly-owned subsidiary. Cheng Yee Wing Betty and Wong See Wai are the managers of MVIL LLC and share voting and dispositive power with respect to the securities held by MVIL LLC. Ms. Cheng and Mr. Wong each disclaim ownership of the securities owned by MVIL LLC. Read SEC document |
| January 11, 2022 Filed Mar 17, 2022 21:14 UTC Amendment | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | ConversionSeries B Preferred Stock · Derivative | 6,410,964 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-011432 · doc4a.xml · derivative · entry 4 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner MVIL, LLC · CIK 0001914583 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 6,410,964 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, are the directors of Morningside Venture Investments Limited ("Morningside") and share voting and dispositive power with respect to the securities held by Morningside and MVIL, LLC ("MVIL LLC"), Morningside's wholly-owned subsidiary. Cheng Yee Wing Betty and Wong See Wai are the managers of MVIL LLC and share voting and dispositive power with respect to the securities held by MVIL LLC. Ms. Cheng and Mr. Wong each disclaim ownership of the securities owned by MVIL LLC. Read SEC document |
| January 11, 2022 Filed Mar 17, 2022 21:14 UTC Amendment | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | ConversionSeries A Preferred Stock · Derivative | 1,409,035 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-011432 · doc4a.xml · derivative · entry 3 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner MVIL, LLC · CIK 0001914583 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,409,035 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, are the directors of Morningside Venture Investments Limited ("Morningside") and share voting and dispositive power with respect to the securities held by Morningside and MVIL, LLC ("MVIL LLC"), Morningside's wholly-owned subsidiary. Cheng Yee Wing Betty and Wong See Wai are the managers of MVIL LLC and share voting and dispositive power with respect to the securities held by MVIL LLC. Ms. Cheng and Mr. Wong each disclaim ownership of the securities owned by MVIL LLC. Read SEC document |
| January 11, 2022 Filed Mar 17, 2022 21:14 UTC Amendment | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | PurchaseCommon Stock | 263,158 | $19.00 | $5,000,002.00 |
DisclosureSEC source: 0000899243-22-011432 · doc4a.xml · nonDerivative · entry 2 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner MVIL, LLC · CIK 0001914583 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 10,678,808 F2 · ownership.nature: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, are the directors of Morningside Venture Investments Limited ("Morningside") and share voting and dispositive power with respect to the securities held by Morningside and MVIL, LLC ("MVIL LLC"), Morningside's wholly-owned subsidiary. Cheng Yee Wing Betty and Wong See Wai are the managers of MVIL LLC and share voting and dispositive power with respect to the securities held by MVIL LLC. Ms. Cheng and Mr. Wong each disclaim ownership of the securities owned by MVIL LLC. Read SEC document |
| January 11, 2022 Filed Mar 17, 2022 21:14 UTC Amendment | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | ConversionCommon Stock | 10,415,650 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-011432 · doc4a.xml · nonDerivative · entry 1 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner MVIL, LLC · CIK 0001914583 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 10,415,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, are the directors of Morningside Venture Investments Limited ("Morningside") and share voting and dispositive power with respect to the securities held by Morningside and MVIL, LLC ("MVIL LLC"), Morningside's wholly-owned subsidiary. Cheng Yee Wing Betty and Wong See Wai are the managers of MVIL LLC and share voting and dispositive power with respect to the securities held by MVIL LLC. Ms. Cheng and Mr. Wong each disclaim ownership of the securities owned by MVIL LLC. F3 · ownership.nature: The shares of Series C-2 Preferred Stock and the Common Stock received upon conversion of the C-2 Preferred Stock are held by MVIL LLC. Read SEC document |
| November 18, 2021 Filed Nov 18, 2021 21:16 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | PurchaseCommon Stock | 250,000 | $40.00 | $10,000,000.00 |
DisclosureSEC source: 0000899243-21-045265 · doc4.xml · nonDerivative · entry 1 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,806,342 F1 · ownership.direct: Frances Anne Elizabeth Richard, Cheung Ka Ho, Jill Marie Franklin and Peter Stuart Allenby Edwards, the directors of Morningside Venture Investments, Ltd. ("MVIL"), share voting and dispositive control over the shares held by MVIL. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 21:11 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | PurchaseCommon Stock | 3,800,000 | $2.60 | $9,880,000.00 |
DisclosureSEC source: 0001104659-20-011907 · a4.xml · nonDerivative · entry 1 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,109,052 F1 · ownership.direct: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments Limited ("MVIL"), share voting and dispositive control over the shares held by MVIL. Read SEC document |
| January 13, 2020 Filed Jan 21, 2020 22:47 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | PurchaseCommon Stock | 540,540 | $37.00 | $19,999,980.00 |
DisclosureSEC source: 0000899243-20-001530 · doc4.xml · nonDerivative · entry 1 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,556,342 F1 · ownership.direct: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments, Ltd. ("MVIL"), share voting and dispositive control over the shares held by MVIL. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 19:32 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | PurchaseCommon Stock | 441,176 | $17.00 | $7,499,992.00 |
DisclosureSEC source: 0001104659-19-014545 · a4.xml · nonDerivative · entry 1 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,015,802 F1 · ownership.direct: Louise Mary Garbarino, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments, Ltd. ("MVIL"), share voting and dispositive control over the shares held by MVIL. Read SEC document |
| September 21, 2018 Filed Sep 24, 2018 22:05 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | PurchaseCommon Stock | 40,000 | $19.84 | $793,600.00 |
DisclosureSEC source: 0000899243-18-025079 · doc4.xml · nonDerivative · entry 3 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,574,626 F3 · price: The reported price is a weighted average price. These shares were purchased on 9/21/2018 in multiple transactions at prices ranging from $19.48 to $20.14, inclusive. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.direct: Louise Mary Garbarino, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments, Ltd. ("MVIL"), share voting and dispositive control over the shares held by MVIL. Read SEC document |
| September 20, 2018 Filed Sep 24, 2018 22:05 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | PurchaseCommon Stock | 21,724 | $19.43 | $422,097.32 |
DisclosureSEC source: 0000899243-18-025079 · doc4.xml · nonDerivative · entry 2 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,534,626 F2 · price: The reported price is a weighted average price. These shares were purchased on 9/20/2018 in multiple transactions at prices ranging from $19.25 to $19.60, inclusive. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.direct: Louise Mary Garbarino, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments, Ltd. ("MVIL"), share voting and dispositive control over the shares held by MVIL. Read SEC document |
| September 20, 2018 Filed Sep 24, 2018 22:05 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | PurchaseCommon Stock | 19,599 | $18.79 | $368,265.21 |
DisclosureSEC source: 0000899243-18-025079 · doc4.xml · nonDerivative · entry 1 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,512,902 F1 · price: The reported price is a weighted average price. These shares were purchased on 9/20/2018 in multiple transactions at prices ranging from $18.25 to $19.24, inclusive. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.direct: Louise Mary Garbarino, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments, Ltd. ("MVIL"), share voting and dispositive control over the shares held by MVIL. Read SEC document |
| September 19, 2018 Filed Sep 19, 2018 23:42 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | PurchaseCommon Stock | 60,000 | $18.09 | $1,085,400.00 |
DisclosureSEC source: 0000899243-18-024796 · doc4.xml · nonDerivative · entry 4 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,493,303 F4 · price: The reported price is a weighted average price. These shares were purchased on 9/19/2018 in multiple transactions at prices ranging from $17.81 to $18.44, inclusive. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.direct: Louise Mary Garbarino, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments, Ltd. ("MVIL"), share voting and dispositive control over the shares held by MVIL. Read SEC document |
| September 18, 2018 Filed Sep 19, 2018 23:42 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | PurchaseCommon Stock | 40,000 | $18.47 | $738,800.00 |
DisclosureSEC source: 0000899243-18-024796 · doc4.xml · nonDerivative · entry 3 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,433,303 F3 · price: The reported price is a weighted average price. These shares were purchased on 9/18/2018 in multiple transactions at prices ranging from $18.23 to $18.96, inclusive. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.direct: Louise Mary Garbarino, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments, Ltd. ("MVIL"), share voting and dispositive control over the shares held by MVIL. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 23:42 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | PurchaseCommon Stock | 8,600 | $18.84 | $162,024.00 |
DisclosureSEC source: 0000899243-18-024796 · doc4.xml · nonDerivative · entry 2 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,393,303 F2 · price: The reported price is a weighted average price. These shares were purchased on 9/17/2018 in multiple transactions at prices ranging from $18.75 to $18.99, inclusive. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.direct: Louise Mary Garbarino, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments, Ltd. ("MVIL"), share voting and dispositive control over the shares held by MVIL. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 23:42 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | PurchaseCommon Stock | 31,400 | $18.50 | $580,900.00 |
DisclosureSEC source: 0000899243-18-024796 · doc4.xml · nonDerivative · entry 1 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,384,703 F1 · price: The reported price is a weighted average price. These shares were purchased on 9/17/2018 in multiple transactions at prices ranging from $17.75 to $18.74, inclusive. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.direct: Louise Mary Garbarino, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments, Ltd. ("MVIL"), share voting and dispositive control over the shares held by MVIL. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 17:14 UTC | Liquidia Technologies Inc LQDA · Entity 145051 | OtherWarrant to purchase Common Stock · Derivative | 18,996 | Not disclosed Strike: $0.01 | Not disclosed |
DisclosureSEC source: 0001104659-18-048810 · a4.xml · derivative · entry 6 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,996 Underlying: Common Stock · 18,996 shares Expires 2026-12-31 F3 · kind: Immediately prior to the closing of the Issuer's initial public offering and without payment of further consideration, the Warrants to purchase Series D Preferred Stock automatically became exercisable to purchase the Issuer's common stock. The transaction is listed solely for the purpose of reporting the change of the title and amount of securities underlying the warrant. F3 · price: Immediately prior to the closing of the Issuer's initial public offering and without payment of further consideration, the Warrants to purchase Series D Preferred Stock automatically became exercisable to purchase the Issuer's common stock. The transaction is listed solely for the purpose of reporting the change of the title and amount of securities underlying the warrant. F4 · ownership.direct: Louise Mary Garbarino, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments, Ltd. ("MVIL"), share voting and dispositive control over the shares held by MVIL. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 17:14 UTC | Liquidia Technologies Inc LQDA · Entity 145051 | OtherWarrant to purchase Series D Preferred Stock · Derivative | 319,664 | Not disclosed Strike: $0.01 | Not disclosed |
DisclosureSEC source: 0001104659-18-048810 · a4.xml · derivative · entry 5 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Series D Preferred Stock · 319,664 shares Expires 2026-12-31 F3 · kind: Immediately prior to the closing of the Issuer's initial public offering and without payment of further consideration, the Warrants to purchase Series D Preferred Stock automatically became exercisable to purchase the Issuer's common stock. The transaction is listed solely for the purpose of reporting the change of the title and amount of securities underlying the warrant. F3 · price: Immediately prior to the closing of the Issuer's initial public offering and without payment of further consideration, the Warrants to purchase Series D Preferred Stock automatically became exercisable to purchase the Issuer's common stock. The transaction is listed solely for the purpose of reporting the change of the title and amount of securities underlying the warrant. F4 · ownership.direct: Louise Mary Garbarino, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments, Ltd. ("MVIL"), share voting and dispositive control over the shares held by MVIL. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 17:14 UTC | Liquidia Technologies Inc LQDA · Entity 145051 | ConversionSeries D Preferred Stock · Derivative | 1,849,490 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-048810 · a4.xml · derivative · entry 4 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 109,909 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series D preferred stock had no expiration date and automatically converted into the Issuer's common stock on approximately a 0.0594-for-1 basis immediately prior to the closing of the Issuer's initial public offering. F2 · derivative.exercise_date: The Series D preferred stock had no expiration date and automatically converted into the Issuer's common stock on approximately a 0.0594-for-1 basis immediately prior to the closing of the Issuer's initial public offering. F2 · derivative.expiration_date: The Series D preferred stock had no expiration date and automatically converted into the Issuer's common stock on approximately a 0.0594-for-1 basis immediately prior to the closing of the Issuer's initial public offering. F4 · ownership.direct: Louise Mary Garbarino, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments, Ltd. ("MVIL"), share voting and dispositive control over the shares held by MVIL. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 17:14 UTC | Liquidia Technologies Inc LQDA · Entity 145051 | ConversionSeries C Preferred Stock · Derivative | 3,420,516 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-048810 · a4.xml · derivative · entry 3 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 442,819 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C preferred stock had no expiration date and automatically converted into the Issuer's common stock on approximately a 0.1295-for-1 basis immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The Series C preferred stock had no expiration date and automatically converted into the Issuer's common stock on approximately a 0.1295-for-1 basis immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The Series C preferred stock had no expiration date and automatically converted into the Issuer's common stock on approximately a 0.1295-for-1 basis immediately prior to the closing of the Issuer's initial public offering. F4 · ownership.direct: Louise Mary Garbarino, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments, Ltd. ("MVIL"), share voting and dispositive control over the shares held by MVIL. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 17:14 UTC | Liquidia Technologies Inc LQDA · Entity 145051 | ConversionCommon Stock | 109,909 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-048810 · a4.xml · nonDerivative · entry 2 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 552,728 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Series D preferred stock had no expiration date and automatically converted into the Issuer's common stock on approximately a 0.0594-for-1 basis immediately prior to the closing of the Issuer's initial public offering. F4 · ownership.direct: Louise Mary Garbarino, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments, Ltd. ("MVIL"), share voting and dispositive control over the shares held by MVIL. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 17:14 UTC | Liquidia Technologies Inc LQDA · Entity 145051 | ConversionCommon Stock | 442,819 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-048810 · a4.xml · nonDerivative · entry 1 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 442,819 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series C preferred stock had no expiration date and automatically converted into the Issuer's common stock on approximately a 0.1295-for-1 basis immediately prior to the closing of the Issuer's initial public offering. F4 · ownership.direct: Louise Mary Garbarino, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments, Ltd. ("MVIL"), share voting and dispositive control over the shares held by MVIL. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:53 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | ConversionSeries B Convertible Preferred Stock · Derivative | 1,007,422 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-039676 · doc4.xml · derivative · entry 5 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,007,422 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.direct: Louise Mary Garbarino, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments Limited ("MVIL"), share voting and dispositive control over the shares held by MVIL. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:53 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | ConversionSeries A Convertible Preferred Stock · Derivative | 1,051,630 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-039676 · doc4.xml · derivative · entry 4 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,051,630 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.direct: Louise Mary Garbarino, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments Limited ("MVIL"), share voting and dispositive control over the shares held by MVIL. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:53 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | PurchaseCommon Stock | 250,000 | $15.00 | $3,750,000.00 |
DisclosureSEC source: 0001209191-18-039676 · doc4.xml · nonDerivative · entry 3 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,309,052 F2 · ownership.direct: Louise Mary Garbarino, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments Limited ("MVIL"), share voting and dispositive control over the shares held by MVIL. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:53 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | ConversionCommon Stock | 1,007,422 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-039676 · doc4.xml · nonDerivative · entry 2 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,059,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.direct: Louise Mary Garbarino, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments Limited ("MVIL"), share voting and dispositive control over the shares held by MVIL. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:53 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | ConversionCommon Stock | 1,051,630 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-039676 · doc4.xml · nonDerivative · entry 1 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,051,630 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.direct: Louise Mary Garbarino, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments Limited ("MVIL"), share voting and dispositive control over the shares held by MVIL. Read SEC document |
| November 13, 2017 Filed Nov 13, 2017 21:26 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | ConversionSeries E Preferred Stock · Derivative | 259,302 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-026032 · doc4.xml · derivative · entry 6 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 121,566 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series B, Series C, Series D and Series E Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B, Series C, Series D and Series E Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series B, Series C, Series D and Series E Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B, Series C, Series D and Series E Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series B, Series C, Series D and Series E Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B, Series C, Series D and Series E Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. Read SEC document |
| November 13, 2017 Filed Nov 13, 2017 21:26 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | ConversionSeries D Preferred Stock · Derivative | 4,476,275 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-026032 · doc4.xml · derivative · entry 5 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,098,581 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series B, Series C, Series D and Series E Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B, Series C, Series D and Series E Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series B, Series C, Series D and Series E Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B, Series C, Series D and Series E Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series B, Series C, Series D and Series E Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B, Series C, Series D and Series E Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. Read SEC document |
| November 13, 2017 Filed Nov 13, 2017 21:26 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | ConversionSeries C Preferred Stock · Derivative | 17,200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-026032 · doc4.xml · derivative · entry 4 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,063,759 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series B, Series C, Series D and Series E Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B, Series C, Series D and Series E Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series B, Series C, Series D and Series E Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B, Series C, Series D and Series E Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series B, Series C, Series D and Series E Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B, Series C, Series D and Series E Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. Read SEC document |
| November 13, 2017 Filed Nov 13, 2017 21:26 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | ConversionSeries B Preferred Stock · Derivative | 1,054,544 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-026032 · doc4.xml · derivative · entry 3 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 494,394 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series B, Series C, Series D and Series E Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B, Series C, Series D and Series E Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series B, Series C, Series D and Series E Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B, Series C, Series D and Series E Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series B, Series C, Series D and Series E Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B, Series C, Series D and Series E Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.